Patient characteristics
| . | APS patients (n = 80) . | |
|---|---|---|
| No VKA (n = 30) . | VKA (n = 50) . | |
| General characteristics | ||
| Age, y | 46 ± 13 | 45 ± 15 |
| Female sex | 27 (90) | 32 (64) |
| Systemic lupus erythematosus | 8 (27) | 18 (36) |
| Primary APS | 22 (73) | 32 (64) |
| Secondary APS | 8 (27) | 18 (36) |
| Laboratory parameters, % | ||
| LA | 67 | 84 |
| Anti-cardiolipin antibodies | 83 | 84 |
| Anti-β2GPI antibodies | 50 | 67 |
| Clinical symptoms | ||
| Arterial thrombosis | 8 (27) | 19 (50) |
| Venous thrombosis | 12 (40) | 31 (62) |
| Small vessel thrombosis | 3 (10) | 17 (34) |
| Arterial and venous thrombosis | 1 (3) | 10 (20) |
| Early fetal loss, female patients | 3 (11) | 0 (0) |
| Late fetal loss, female patients | 6 (22) | 5 (16) |
| Placental complications, female patients | 2 (7) | 3 (9) |
| . | APS patients (n = 80) . | |
|---|---|---|
| No VKA (n = 30) . | VKA (n = 50) . | |
| General characteristics | ||
| Age, y | 46 ± 13 | 45 ± 15 |
| Female sex | 27 (90) | 32 (64) |
| Systemic lupus erythematosus | 8 (27) | 18 (36) |
| Primary APS | 22 (73) | 32 (64) |
| Secondary APS | 8 (27) | 18 (36) |
| Laboratory parameters, % | ||
| LA | 67 | 84 |
| Anti-cardiolipin antibodies | 83 | 84 |
| Anti-β2GPI antibodies | 50 | 67 |
| Clinical symptoms | ||
| Arterial thrombosis | 8 (27) | 19 (50) |
| Venous thrombosis | 12 (40) | 31 (62) |
| Small vessel thrombosis | 3 (10) | 17 (34) |
| Arterial and venous thrombosis | 1 (3) | 10 (20) |
| Early fetal loss, female patients | 3 (11) | 0 (0) |
| Late fetal loss, female patients | 6 (22) | 5 (16) |
| Placental complications, female patients | 2 (7) | 3 (9) |
Values represent n (%) of patients, unless otherwise indicated.